logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Ruxolitinib cream for vitiligo

< Back

Ruxolitinib cream for vitiligo

Drugs

Skin Disease, Burns and Wound Care

August 2021


Ruxolitinib cream is in development for the treatment of vitiligo. Vitiligo is a common chronic skin condition where white patches develop on the skin, commonly on the hands and face. The condition is not life-threatening but can have an impact on self-esteem and wellbeing of sufferers. Risk factors include other autoimmune diseases and family history of the disease. The cause of vitiligo is not fully understood but it is thought it may be an autoimmune condition. There are no licensed treatments specifically for vitiligo which highlights the unmet need of these patients.

Ruxolitinib cream is a topical formulation of the active substance ruxolitinib. Ruxolitinib works as a selective inhibitor by blocking the proteins which are involved in the downstream signalling of the immune system. Preventing the binding of these proteins reduces the immune response. If licensed, administered topically, ruxolitinib cream would offer a pharmacological treatment for patients with vitiligo who currently rely on non-specific and/or unlicensed medicines to treat their condition.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts